论文部分内容阅读
为了研究血清和尿液中新喋呤、血清LDH和β2微球蛋白的表达水平与非霍奇金淋巴瘤疗效的相关性,采用酶联免疫吸附试验(ELISA法)检测27例非霍奇金淋巴瘤患者治疗前后血清和尿液中的新喋呤含量,同时检测血清LDH水平和血清β2微球蛋白含量,分析比较治疗前血清和尿液中的新喋呤水平、血清LDH、β2微球蛋白与患者疗效的关系。研究结果显示:完全缓解和部分缓解的患者治疗前后的血清和尿液中新喋呤水平、血清LDH、β2微球蛋白值均明显低于稳定和进展组患者(P<0.05)。结论:治疗前血清和尿液中新喋呤值、血清LDH、β2微球蛋白值均可作为预测非霍奇金淋巴瘤疗效的重要指标,其中检测尿液中新喋呤值更为稳定和方便。
In order to investigate the relationship between neopterin, serum LDH and β2-microglobulin levels in serum and urine and the efficacy of non-Hodgkin’s lymphoma, ELISA was used to detect 27 non-Hodgkin’s Serum and urine neopterin levels in patients with lymphoma before and after treatment, serum LDH levels and serum β2 microglobulin levels at the same time, analysis of serum and urine before treatment, neopterin levels, serum LDH, β2 microspheres Relationship between protein and patient’s curative effect. The results showed that the levels of neopterin, serum LDH and β2 microglobulin in serum and urine of patients with complete remission and partial remission before and after treatment were significantly lower than those in stable and progression patients (P <0.05). Conclusions: The values of neopterin, serum LDH, β2 microglobulin in serum and urine before treatment can be used as important indexes to predict the efficacy of non-Hodgkin’s lymphoma. The detection of neopterin in urine is more stable and Convenience.